ImpriMed Inc
- CMO, CRO
- Diagnostics
- Medical device or technology
- Biotech or pharma, therapeutic R&D
ImpriMed accelerates cancer therapy development through live-cell analytics, artificial intelligence, and comparative oncology. With over 9,000 canine and feline and 500 human cases analyzed, and a robust dataset integrating genomics, immunophenotyping, and clinical outcomes, we help pharma teams identify targets, predict responses, and refine inclusion criteria.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}